THRIVENT FINANCIAL FOR LUTHERANS - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.

Quarter-by-quarter ownership
THRIVENT FINANCIAL FOR LUTHERANS ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$76,944
+2.6%
2,014,233
-3.1%
0.18%
+7.0%
Q2 2023$74,984
+82.4%
2,078,838
+93.1%
0.17%
+71.0%
Q1 2023$41,119
-21.4%
1,076,716
+17.1%
0.10%
-26.5%
Q4 2022$52,327
-99.9%
919,636
-30.2%
0.14%
-4.9%
Q3 2022$52,104,000
-10.7%
1,317,732
-0.6%
0.14%
-7.7%
Q2 2022$58,346,000
-0.3%
1,326,058
-9.6%
0.16%
+36.0%
Q1 2022$58,502,000
+35.1%
1,466,968
+36.2%
0.11%
+35.7%
Q4 2021$43,300,000
+41.3%
1,076,833
+43.0%
0.08%
+35.5%
Q3 2021$30,642,000
-12.1%
753,248
-1.9%
0.06%
-12.7%
Q2 2021$34,862,000
+13.9%
767,708
+4.6%
0.07%
+6.0%
Q1 2021$30,599,000
-42.5%
733,976
-41.1%
0.07%
-45.5%
Q4 2020$53,243,000
+70.3%
1,246,615
+4.8%
0.12%
+46.4%
Q3 2020$31,268,000
-1.1%
1,189,801
+0.9%
0.08%
-11.6%
Q2 2020$31,619,000
+49.7%
1,179,378
+0.4%
0.10%
+25.0%
Q1 2020$21,124,000
+1.2%
1,174,208
-0.3%
0.08%
+28.8%
Q4 2019$20,876,000
-65.2%
1,177,440
-69.5%
0.06%
-68.3%
Q3 2019$59,957,000
-7.8%
3,865,719
+2.1%
0.19%
-6.1%
Q2 2019$65,038,000
+10.1%
3,785,665
+3.2%
0.20%
+6.5%
Q1 2019$59,084,000
+13.4%
3,669,830
+3.0%
0.19%
-1.1%
Q4 2018$52,120,000
-8.5%
3,562,505
+13.6%
0.19%
+5.0%
Q3 2018$56,976,000
+45.8%
3,135,730
+35.4%
0.18%
+40.9%
Q2 2018$39,073,0002,316,1370.13%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders